New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1087-1100

  Bunn Jr , Paul A ^a   Kelly, Karen ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PODOPHYLLOTOXIN; TENIPOSIDE; TOPOTECAN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PACLITAXEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TAXOIDS; TOPOTECAN; VINBLASTINE;

EID: 0013594517     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Cook, R. M., Miller, Y., and Bunn, P. A., Jr. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr. Probl. Cancer, 17: 69-144, 1993.
2. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 539: 1-15, 71-85, 1992.
3. Parker, S. L., Tong, T, Bolden, S., and Wingo, P. A. Cancer Statistics. CA: Cancer J. Clin., 47: 5-27, 1997.
4. Ihde, D. C. Chemotherapy of lung cancer. N. Engl. J. Med., 327: 1434-1441, 1992.
5. Soquet, P. J., Chauvin, F., Boissel, J. P., Cellerino, R., Cormier, Y., Ganz, P. A., Kaasa, S., Pater, J. L, Quoix, E., Rapp, E., Tunarello, D., Williams, J., Woods, B. L., and Bernard, J. P. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet, 342: 19-21, 1993.
6. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J., 311: 899-909, 1995.
7. Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., and Inveinizzi, F. Chemotherapy versus supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest, 106: 861-865, 1994.
8. Bunn, P. A., Jr. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin. Oncol., 16: 10-21, 1989.
9. Bunn, P. A., Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin. Oncol., 16: 27-33, 1989.
10. LeChevalier, T., Pujol, J. L., Douillard, J. Y., Alberola, V., Monnier, A., Riviere, A., Liane, P., Chomy, P., Cigolari, Besson, F., Berthaud, P., and Brisgand, D. A three arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin. Oncol., 21: 28-33, 1994.
11. Billingham, L. J., Cullen, M. H., Woods, J., Chetiyawardana, A. D., Joshi, R. C., Cook, J., and Woodroffe, C. M. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: results of a randomized trial evaluating palliation and quality of life. Lung Cancer, 18 (Suppl. 1): 9, 1997.
12. American Society of Clinical Oncology. Special article: clinical practice guidelines for treatment of unresectable non-small cell lung cancer. J. Clin. Oncol., 15: 2996-3018, 1997.
13. Albain, K. S., Crowley, J. J., LeBlane, M., and Livingston, R. B. Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol., 9: 1618-1626, 1991.
14. Crawford, J., O'Rourke, M., Schiller, J. H., Spiridonidis, C. H., Yanovich, S., Ozer, H., Langleben, A., Hutchins, L., Koletsky, A., Clamon, G., Burman, S., White, R., and Hohneker, J. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J. Clin. Oncol., 14: 2777-2784, 1996.
15. Depierre, A., Lebeau, B., Chastang, C., Besenval, M., Quoix, E., Blanchon, F., Zuck, P., Lemarie, E., Milleron, B., Jacoulet, P., Brechot, J. M., Clavier, J., Moro, D., Herman, D., Tuchais, E., Delaude, P., Cordier, J. F., Badri, N., and the French Cooperative Oncology Group-France. Results of a Phase III randomized study of vinorelbine versus vinorelbine cisplatin in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 12: 340, 1993.
16. Depierre, A., Lemarie, E., DeBouis, G., Gamier, G., Jocoulet, P., and Dalphin, J. C. A Phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am. J. Clin. Oncol., 14: 115-119, 1991.
17. Volkes, E. E., Rosenberg, R. K., Jahanzeb, M., Craig, J. B., Gralla, R. J., Belani, C. P., Jones, S. E. Bigley, J. W., and Hohneker, J. A. Multicenter Phase II study of weekly oral vinorelbine for stage IV non-small cell lung cancer. J. Clin. Oncol., 13: 637-644, 1995.
18. Furuse, K., Kubota, K., Kawahara, M., Ogawara, M., Kinuwaki, E., Montomiya, M., Nishiwaki, Y., Niitani, H., and Sakuma, A. A Phase II study of vinorelbine, a new derivative of Vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer, 11: 385-391, 1994.
19. Rapp, E., Pater, J. L., Willan, A., Cormier, Y., Murray, N., Evans, W. K., Hodson, D. I., Clark, D. A., Feld, R., Arnold, A. M., Ayoulo, J. I., Wilson, K. S., Latreille, J., Wierzbicki, R. F., and Hill, D. P. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: a report of a Canadian multicenter randomized trial. J. Clin. Oncol., 6: 633-641, 1988.
20. Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D., and Johnson, D. Phase II study of Taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst., 85: 388-394, 1993.
21. Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., Krakoff, I. H., and Kong, W. K. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl. Cancer Inst., 85: 384-396, 1993.
22. Tan, V., Herrera, C, Einzroj, A. I., and Wiernik, H. Taxol is active as a 3 hour or 24 hour infusion in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 14: 366, 1995.
23. Millward, M. J., Bishop, J. F., Friedlander, M., Levi, J. A., Goldstein, D., Olver, I. N., Smith, J. G., Toner, G. C., Rischin, D, and Bell, D. R. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J. Clin. Oncol., 14: 142-148, 1996.
24. Gatzemeier, U., Heckmeyr, M., Neuhauss, R., Schluter, I., Pawel, J. V., Wagner, H., and Dreps, A. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer, 12 (Suppl. 2): 101-106, 1995.
25. Sekine, I., Nishiwaki, Y., Watanabe, K., Yoneda, S., Saijo, N., and the East Japan Paclitaxel Study Group. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin. Cancer Res., 2: 941-946, 1996.
26. Hainsworth, J. D., Thompson, D. S., and Greco, F. A. Paclitaxel by one-hour infusion: an active drug in metastatic non-small cell lung cancer. J. Clin. Oncol., 13: 1609-1614, 1995.
27. Tester, W. J., Jin, P. Y., Reardon, D. H., Cohn, J. B., and Cohen, M. H. Phase II study of patients with metastatic non-small cell lung carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer (Phila.), 79: 724-729, 1997.
28. Akerly, W., Glantz, M., Choy, H., Rege, V., Sambandam, S., Joseph, P., Yee, L., Rodrigues, B., Wingate, P., and Leone, L. Phase II trial of weekly paclitaxel in advanced non-small lung cancer. J. Clin. Oncol., 16: 153-158, 1998.
29. Ranson, M. R., Jayson, G., Perkins, S., Anderson, H., and Thatcher, N. Single agent paclitaxel in non-small cell lung cancer: single center study using a 3-hour administration schedule. Semin. Oncol., 24 (Suppl. 12): 12-16, 1997.
30. Burns, H., Eckardt, J., Fields, S., Rodriguez, G., Smith, L., Thurman, A., Peacock, N., Kuhn, J., Hodges, S., Bellet, R., Bayssas, M., LeBail, N., and Von Hoff, D. Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 12: 335, 1993.
31. Cerny, T., Kaplan, S., Pavlidis, N., Schoffski, P., Epelbaum, R., van Meerbeeck, J., Wanders, J., Franklin, H. R., and Kaye, S. Docetaxel (Taxotere) is active in non-small cell lung cancer: a Phase II trial of the EORTC early clinical trials group (LCTG). Br. J. Cancer, 70: 384-387, 1994.
32. Fossella, F. V., Lee, J. S., Murphy, W. K., Lippman, S. M., Calayag, M., Pang, A., Chasen, M., Shin, D. M., Glisson, B., Benner, S., Huber, M., Perez-Soler, R., Hong, W. K., and Raber M. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J. Clin. Oncol., 12: 1238-1244, 1994.
33. Francis, P. A., Rigas J. R., Kris, M. G., Pisters, K. M., Orazem, J. P., Woolley, K. J., and Heelan, R. T. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J. Clin. Oncol., 12: 1232-1237, 1994.
34. 2 with prednisone premedication in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 13: 364, 1994.
35. Kunitoh, H., Watanabe, K., Onoshi, T., Furuse, K., Niitani, H., and Taguchi, T. Phase II trial of docetaxel in previously untreated, advanced non-small cell lung cancer: a Japanese cooperative study. J. Clin. Oncol., 14: 1649-1655, 1996.
36. Yokoyama, A., Kurita, Y., Watanabe, K., Negoro, S., Ogura, T., Nakano, M., Minoda, S., Niitani, H., and Taguchi, T. Early Phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Jpn. J. Cancer Chemother., 21: 2609-2616, 1994.
37. Kudo, S., Hino, M., Fujita, A., Igarashi, T., Niitani, H., and Taguchi, T. Late Phase II clinical study of RP56976 in patients with non-small cell lung cancer. Jpn. J. Cancer Chemother., 21: 2617-2623, 1994.
38. Richards, F., White, D., Muss, H., Powell, B., Cruz, J., Andes, A., Spell, N., Tarassoff, P., and Matt, J. Phase I trial of gemcitabine over 30 minutes in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 13: 344, 1994.
39. Fossella, F. V., Lippman, S. M., Shin, D. M,. Tarassoff, P., Calayag-Jung, M., Perez-Soler, R., Lee, J. S., Murphy, W. K., Glisson, B., Rivera, E., and Hong, W. K. Maximum tolerated dose defined for single agent gemcitabine: a Phase I dose escalation study in advanced chemotherapy naive patients with non-small cell lung cancer. J. Clin. Oncol., 15: 310-316, 1997.
40. Abratt, R. P., Bezwoda, W. F., Falkson, G., Goedhals, L., Hacking, D., and Rugg, T. A. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a Phase II study. J. Clin. Oncol., 12: 1535-1540, 1994.
41. Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., and Hansen, H. H. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a Phase II study. J. Clin. Oncol., 12: 1821-1826, 1994.
42. Gatzemeier, U., Shepherd, F. A., LeChevalier, T., Weynants, P., Cottier, B., Groen, H. J., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., Burkes, R. L., Gottfried, M., and Voi, M. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter, extended Phase II study. Eur. J. Cancer, 32: 243-248, 1996.
43. Nakai, Y., Takada, M., Yokoyama, A., Negoro, S., Kurita, Y., Fukuoka, M., and Niitani, H. Results of Phase II studies of gemcitabine in patients with non-small cell lung cancer in Japan. Lung Cancer, 11 (Suppl. 1): 120, 1994.
44. LeChevalier, T. Single agent activity of gemcitabine in advanced non-small cell lung cancer. Semin, Oncol., 23 (Suppl.): 36-42, 1996.
45. Perng, R. P., Chen, Y. M., Ming-Liu, J., Tsai, C. M., Lin, W. C., Yang, K. Y., and Whang-Peng, J. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a Phase II randomized study. J. Clin. Oncol., 15: 2097-2102, 1997.
46. Manegold, C. H., Stahel, R., Mattson, K., Ricci, S., van Valree, N. C., Bergman, R., and ten Bokkel Huinink, W, W. (on behalf of a European multinational study group). Randomized Phase II study of gemcitabine (GEM) monotherapy versus cisplatin plus etoposide (C/E) in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 16: 1651, 1997.
47. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T., for the CPT-11 Lung Cancer Study Group. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
48. Negoro, S., Fukuoka, M., Niitani, H., Suzuki, A., Nakabayashi, T., Kimura, M., Motomiya, M., Kurita, Y., Hasegawa, K., and Kuriyama, T. A Phase II study of CPT-11: a camptothecin derivative in patients with primary lung cancer. Jpn. J. Cancer Chemother., 18: 1013-1019, 1991.
49. Baker, L., Khan, R., Lynch, T., Savaraj, N., Sandler, A., Feun, L., Schaser, R., Hanover, C., and Petit, R. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 16: 1658, 1997.
50. Nakai, H., Fukuoka, M., Furuse, K., Nakao, I., Yoshimori, K., Ogura, T., Hara, N., Sakata, Y., Saito, H., and Hasegawa, K. An early Phase II study of CPT-11 for primary lung cancer. Jpn. J. Cancer Chemother., 18: 607-612, 1991.
51. Douillard, J. Y., Ibrahim, N., Riviere, A., Spaeth, D., Chomy, P., Soussan, K., and Mathieu-Boue, A. Phase II study of CPT-11 in non-small lung cancer. Proc. Am. Soc. Clin. Oncol., 14: 365, 1995.
52. Perez-Soler, R., Glisson, B. S., Kane, J., Lee, J., Raber, M. N., and Hong, W. K. Phase II study of topotecan in patients with non-small cell lung cancer previously untreated. Proc. Am. Soc. Clin. Oncol., 13: 363, 1994.
53. Lynch, T. J., Kalish. L., Strauss, G., Elias, A., Skarin, A., Shulman, L. M., Posner, M., and Freii, E., III. Phase II study of topotecan in metastatic non-small cell lung cancer. J. Clin. Oncol., 12: 347-352, 1994.
54. Hochester, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
55. Kindler, H. L., Kris, M. G., Smith, I. E., Slevin, M. L., and Krebs, J. B. Continuous infusion topotecan as first-line therapy in patients with non-small cell lung cancer (NSCLC): a Phase II study. Proc. Am. Soc. Clin. Oncol., 16: 1697, 1997.
56. Perez-Soler, R., Khuri, F., Pisters, K. M., Robinson, R., Wimberly, A., Lee, J. K., and Fossella, F. V. Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. Proc. Am. Soc. Clin. Oncol., 16: 1619, 1997.
57. Wozniak, A., Crowley, J., Balcerzak, S., Weiss, G. R., Laufman, L. R., Baker, L. H., Fisher, R. I., Bearman, S. I., Taylor, S. A., and Livingston, R. B. Randomized Phase III trial of cisplatin versus cisplatin + Navelbine in treatment of advanced non-small cell lung cancer: a report of a Southwest Oncology Group Study. Proc. Am. Soc. Clin. Oncol., 15: 374, 1996.
58. Berthaud, P., LeChevalier, T., Ruffie, P., Baldeyrou, P., Arriagada, R., Besson, F., and Tursz, T. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur. J. Cancer, 11: 1863-1865, 1992.
59. Brooks, B. J., Gralla, R. J., McGaw, H. J., Otten, M. C., Lang, A. C., and Rittenberg, C. N. Cisplatin plus vinorelbine (Navelbine) combination chemotherapy for advanced non-small cell lung cancer: testing the efficacy of a regimen designated to reduce toxicity and increase dose intensity. Proc. Am. Soc. Clin. Oncol., 13: 348, 1994.
60. Westeel, V., Jacoulet, P., Breton, J. L., Gamier, G., Mercier, M., and Depierre, A. Phase II study of alternating doses of vinorelbine in combination with cisplatin for non-small cell lung cancer (NSCLC): a disappointing experience. Lung Cancer, 16: 61-73, 1996.
61. Depierre, A., Chastang, C., Quoix, E., Lebeau, B., Blanchon, F., Paillot, N., Lemarie, E., Milleron, B., Moro, D., and Clavier, J. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann. Oncol., 5: 37-42, 1994.
62. Bretti, S., Berriti, A., Gorzegno, G., La Ciura, P., Paze, E., Celano, A., Grecchi, G., Perroni, D., Bumma, C., and Dogliotti, L. Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Lung Cancer, 14: 353-360, 1996.
63. Gebbia, V., Caruso, M., Valenza, R., Testa, A., Cannata, G., Verderame, F., Cipolla, C., Curto, G., Oliveri, D., Chiarenza, M., Latteri, M. A., Gesu, G. D., and Gebbia, N. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non-small cell lung carcinoma. Anticancer Res., 14: 1247-1249, 1994.
64. Frontini, L., Candido, P., Cattaneo, M. T., Zonato, S., Piatto, E., Scapaticci, R., Isa, L., Raina, A., Lanzetti, V., Pavia, G., Legnani, W., Filipazzi, V., Rho, B., and Piazza, E. Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer. Tumori, 82: 57-60, 1996.
65. Spiridonidas, C. H., Laufman, L. R., Jones, J. J., Rhodes, V. A., and Wallace, K. Phase II trial of daily X 4 Navelbine-cisplatin in advanced non-small cell lung cancer (NSCLC): a preliminary report. Proc. Am. Soc. Clin. Oncol., 16: 1737, 1997.
66. von Pawel, J., Wagner, H., Niederle, N., Heider, A., Koschel, G., Gromotka, E., and Hanske, M. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol., 23 (Suppl. 16): 47-50, 1996.
67. Klastersky, J., and Sculier, J. P. Dose finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. Lung Cancer, 12 (Suppl. 2): S117-S125, 1995.
68. Belli, L., LeChevalier, T., Gottfried, M., Adams, D., Ruffie, P., le Cesne, A., Tete, L., and Pellae-Cosset, B. Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 14: 350, 1995.
69. Pirker, R., Krajnik, G., Zochhauser, S., Malayeri, R., Kneussl, M., and Huber, H. Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 6: 833-835, 1995.
70. Georgiadis, M. S., Schuler, B. S., Brown, J. E., Kieffer, L. V., Steinberg, S. M., and Wilson, W. H., Takimoto, C. H., Kelley, M. J., and Johnson, B. E. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a Phase I trial in patients with advanced lung cancer. J. Clin. Oncol., 15: 735-743, 1997.
71. Sorenson, J. B., Wederang, K., Hansen, H. H., and Dombernowsky, P. Phase II study of paclitaxel and cisplatin in biweekly schedule for non-resectable non-small cell lung cancer. Semin. Oncol., in press, 1997.
72. Rowinsky, E., Chaudhry, V., Forastierre, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., and Donehower, R. C. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocytc colony stimulating factor: neuromuscular toxicity is dose limiting. J. Clin. Oncol., 11: 2010-2020, 1993.
73. Niederle, N., Heider, A., Von Pawel, J., Wagner, J., Koschel, R., Hanske, M., and Kettner, H. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 16: 476a, 1997.
74. Bonomi, P., Kim, K., Chang, A., and Johnson, D. Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin-G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group trial. Proc. Am. Soc. Clin. Oncol., 15: 382, 1996.
75. Giaccone, G., Postmus, P., Debruyne, C., Splinter, T., Diaz-Puente, M., van Zandwijk, N., Ardizzonie, A., Scagliotti, G., van Meerbeeck, J., Festen, J., Curran, D., Sahmould, T., and the EORTC LCCG. Final results of an EORTC Phase III study of paclitaxel versus teniposide, in combination with cisplatin in advanced NSCLC. Proc. Am. Soc. Clin. Oncol., 16: 460a, 1997.
76. Splinter, T. A. W., Bahmoud, T., Festen, J., van Zandwijk, N., Sorenson, S., Clerico, M., Burghouts, J., Dautzenberg, B., Kho, G. S., Kirkpatrick, A., and Giaccone, G. Two schedules of teniposide with or without cisplatin in advanced non-small cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol., 14: 127-134, 1996.
77. Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., and Ozols, R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a Phase II toxicity, response and survival analysis. J. Clin. Oncol., 13: 1360-1370, 1995.
78. Johnson, D. H., Paul, D. M., Hande, K. R., and DeVore, R. F., III. Paclitaxel (Taxol) plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University Phase II trial-LUN 46. Semin. Oncol., 22 (Suppl. 9): 30-33, 1995.
79. Belani, C. P., Aisner, J., Hiponia, D., and Engstrom, C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol., 22 (Suppl. 9): 7-12, 1995.
80. Bunn, P. A., and Kelly, K. A Phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center Study. Clin. Cancer Res., 3: 1117-1123, 1997.
81. Natale, R. B. Preliminary results of a Phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol., 23 (Suppl. 16): 51-54, 1996.
82. Rowinsky, E. K., Flood, W. A., Sartorius, S. E., Bowling, K. M., and Ettinger, D. S. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin. Oncol., 22 (Suppl. 9): 48-54, 1995.
83. Hainsworth, J. D., Thompson, D. S., Urba, W. J., Hon, J. K., Thompson, K. A., Hopkins, L. G., and Greco, F. A. One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer: results of a Minnie Pearl Cancer Research Network Phase II study. Lung Cancer, 18 (Suppl. 1): 23-24, 1997.
84. Evans, W. K., Steward, D. J., Tomiak, E., Goss, G., Logan, D., Dulude, H., and Gallant, G. Carboplatin and paclitaxel by one hour infusion for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 14: 374, 1995.
85. Belani, C. P., Bonomi, P., Dobbs, T., DeVore, R., Ettinger, D., Jett, J., Kozak, C., Cohen, L., Capozzoli, M. J., and Johnson, D. Docetaxel and cisplatin combination in patients with non-small cell lung cancer: a multicenter Phase II trial. Lung Cancer, 18 (Suppl. 1): 12-13, 1997.
86. Karato A., Hayashi I., Segawa Y., Hiraki, S., Harada, M., Yamakido, M., Ueda, N., Tominaga, K., Watanabe, K., and Nitani, H. Phase I/II study of docetaxel (TXT) and cisplatin (CDDP) in patients with previously untreated metastatic non-small cell lung cancer. Lung Cancer, 18 (Suppl. 1): 11, 1997.
87. Georgoulias, V., Androulakis, N., Dimopoulous, A. M., Kourousis, C., Kakolyris, S., Papadakis, E., Apostolopoulou, F., Papadimitriou F., Vossos, A., Aggelidou M., Heras, P., Tzannes, S., Souglakos, J., and Hatzidaki, D. Treatment of non-small cell lung cancer stages IIIB and IV with docetaxel and cisplatin. Lung Cancer, 18 (Suppl. 1): 44, 1997.
88. Mattson, K., Vansteenkiste, J., Saarinen, A., Bargetzi, M., Fillet, G., Teixeira, E., Gatzemeier, U., Soulas, F., Soussan-Lazard, K., Berille, J., Bougon, N., and Jekunen, A. A Phase II study of docetaxel (Taxotere) alternating with cisplatin with full doses of both drugs for advanced NSCLC. Lung Cancer, 18 (Suppl. 1): 19, 1997.
89. Berille, J., LeChevalier, T., and Zalcberg, J. R. Overview of Taxotere-cisplatin combination in non-small cell lung cancer. Ann. Oncol., 7 (Suppl. 5): 90, 1996.
90. Peters, G. J., Bergman, A. M., Ruiz van Haoeren, V. W., Veerman, G., Kuiper, C. M., and Braakhuis, B. J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol., 22 (Suppl. 11): 72-79, 1995.
91. Steward, W. P., Dunlop, D. J., Cameron, C., Talbot, D. C., Kleisbaver, F. P., Thomas, P., Guerin, F. C., Perol, M., Sanson, C., Dabouis, G., and Lacroix, H. Gemcitabine plus cisplatin in non-small cell lung cancer: a Phase I/II study. Eur. J. Cancer, 31A (Suppl. 5): S225, 1995.
92. Abratt, R., Bezowda, W., Goedhals, L., and Hacking, D. J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for ad-vanced non-small cell lung cancer. J. Clin. Oncol., 15: 744-749, 1997.
93. Shepherd, F., Cormier, Y., Evans, W. K., Burkes, R., Goss, G., Klimo, P., Feld, R., Binder, C., and Iglesias, J. A Phase II study of gemcitabine and cisplatin weekly X 3 every 4 weeks in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 15: 380, 1996.
94. Crino, L., Scagliotti, G., Figoli, F., Clerici, M., DeMarinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., Paccagnella, A., Adamo, V., Altavilla, G., Incoronato, P., Trippetti, M., Mosconi, A. M., Santucci, A., Sorbolini, S., Oliva, C., and Tonato, M. Cisplatin-gemcit-abine combination in advanced non-small cell lung cancer: a Phase II study. J. Clin. Oncol., 15: 297-303, 1997.
95. Sandler, A. B., Ansari, R., McClean, J., Fisher, W., Dorr, F. A., and Einhorn, L. H. Gemcitabine plus cisplatin in non-small cell lung cancer: a Phase H study. Eur. J. Cancer, 31A (Suppl. 5): S225, 1995.
96. Anton, A., Carrato, A., Gonzalez Larriba, J. L., Vadel, C., Masutti, B., Montalar, J., Aranda, E., Barnetto, J., Tarazona, Y., and Lopez-Martin, E. Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 15: 380, 1996.
97. Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K., and Kishimoto, S. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J. Clin. Oncol., 10: 1775-1780, 1992.
98. Masuda, N., Fukuoka, M., Kudoh, S., Kudoh, S., Kusunoki, Y., Matsui, K., Nakagawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yana, T., Negoro, S., Takifuji, N., and Takada, M. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer. J. Clin. Oncol., 12: 90-96, 1994.
99. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Takifuji, N., Nakagawa, K., Tamanoi, M., Nitta, T., Hirashima, T., Negoro, S., and Takada, M. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br. J. Cancer, 68: 777-782, 1993.
100. Nitta, T., Takada, M., Hirashima, T., Tamanoi, M., Masuda, N., Kudoh, S., Kusunoki, Y., Matsui, K., Nakagawa, K., Takifuji, N., Negoro, S., and Fukuoka, M. Phase I and pharmacologic study of irinotecan in combination with cisplation for advanced lung cancer. Proc. Am. Assoc. Cancer. Res., 34: 206, 1993.
101. Mori, K., Suga, V., Kishero, I., Ohta, S., and Tominaga, K. A Phase I study of CPT-11 and cisplatin (5 day continuous infusion) for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 13: 366, 1994.
102. Mori, K., Hirose, T., and Tominaga, K. Phase II study irinotecan and infusional cisplatin with recombinant human granulocyte colonystimulating factor support in the treatment of advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol, 16: 1714, 1997.
103. DeVore, R., Crawford, J., Dimery, J., Echardt, G., Kasunic, D., Demke, D., and Gorris, G. Phase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC. Proc. Am. Soc. Clin. Oncol., 16: 1674, 1997.
104. Wiesenfeld, M., Marks, R., Grill, J., Sloan, J., Tazelaar, H., Carroll, T., Kugler, J., and Krook, J. A randomized Phase II study of topotecan (TOPA) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel (Taxol) with filgrastim in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 16: 1755, 1997.
105. Albain, K. S., Rusch, V. W., Crowley, J. J., Rice, T. W., Turrisi, A. T., III, Weick, J. K., Lonchyna, V. A., Presant, C. A., McKenna, R. J., Gandara, D. R., Fosmire, H., Taylor, S., Stelzer, K., Beasley, K., and Livingston, R. Concurrent cisplatin/etoposide + chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J. Clin. Oncol., 13: 1880-1892, 1995.
106. Jaakinainen, L., Goodwin, P. J., Pater, L., Warde, P., Murray, N., and Rapp, E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J. Clin. Oncol., 8: 1301-1309, 1990.
107. Smith, T. J., Hillner, B. E., Neighbors, D. M., McSorley, P. A., and LeChevalier, T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin and vindesine plus cisplatin. J. Clin. Oncol., 13: 2166-2173, 1995.
108. Copley-Merriman, C., Corral, J., King, K., Whiteside, R., Voi, M., Dorr, F. A., and McDonald, R. C. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer, 14: 45-61, 1996.
109. Elit, L. M., Gafrei, A., and Levine, M. N. Economic and policy implications of adopting paclitaxel as first line therapy for advanced ovarian cancer: an Ontario perspective. J. Clin. Oncol., 15: 632-639, 1997.
110. McGuire, W., Neugut, A. I., Airkian, S., Doyle, J., and Deseii, C. M. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J. Clin. Oncol., 15: 640-645, 1997.
111. Roth, B. J., Johnson, D. H., Einhorn, L. H., Schacter, L. P., Chering, N. C., Cohen, H. J., Crawford, J., Randolph, J. A., Goodlow, J. L., Broun, G. O., Omura, G. A., and Greco, F. A. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol., 10: 282-291, 1992.
112. Fukuoka, M., Furuse, K., Saijo, N., Nishiwaki, Y., Ikegami, H., Tamura, T., Shimoyama, M., and Svermasu, K. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J. Natl. Cancer Inst., 83: 855-861, 1991.
113. Pritchard, R. S., and Anthony, S. P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable non-small cell lung cancer. Ann. Int. Med., 125: 723-729, 1996.
114. Kubota, K., Furuse, K., Kawahara, M., Kodama, N., Yamamoto, M., Ogawara, M., Negoro, S., Masuda, N., Takada, M., Matsui, K., Takifuji, N., Kudoh, S., Kusunoki, Y., and Fukuoka, M. Role of radiotherapy in combined modality treatment of locally advanced non-small cell lung cancer. J. Clin. Oncol., 12: 1547-1552, 1994.
115. Bunn, P. A., Jr., Crowley, J., Kelly, K., Hazuka, M. B., Beasley, K., Upchurch, C., Livingston, R., Weiss, G. R., Hicks, W. J., and Gandara, D. R. Chemoradiotherapy with or without GM-CSF in the treatment of limited stage small cell lung cancer: a prospective Phase III randomized study of the Southwest Oncology Group. J. Clin. Oncol., 13: 1362-1341, 1995.
116. Johnson, D. H., Kim, K., Sause, W., Komaki, R., Wagner, H., Aisner, S., Livingston, R., Blum, R., and Turrisi, A. T. Cisplatin and etoposide plus thoracic radiotherapy administered once or twice daily in limited stage small cell lung cancer: final report of intergroup study 0096. Proc. Am. Soc. Clin. Oncol., 15: 374, 1996.
117. Dillman, R. O., Herndon, J., Seagren, S. L., Eaton, W. L., Jr., and Green, M. R. Improved survival in stage III non-small cell lung cancer: seven year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J. Natl. Cancer Inst., 88: 1210-1215, 1996.
118. Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Baat, B., Nijs, A. Renaud, A., Rodrigus, P., Schuster-Uitterhoeve, L., Sculier, J-P., Zandwijk, N. V., and Bartelink, H. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. New Engl. J. Med., 326: 524-530, 1992.
119. Jeremic, B., Shibamoto, Y., Acimovic, L., and Milisavljevic, S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J. Clin. Oncol., 14: 1065-1070, 1996.
120. Hazuka, M., Crowley, J. J., Bunn, P. A., Jr., O'Rourke, M., Braun, T. J., and Livingston, R. B. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small cell lung: results of a Phase II Southwest Oncology Group Study. J. Clin. Oncol., 12: 1814-1820, 1994.
121. Kelly, K., Bunn, P. A., Jr., Hazuka, M., Leonard, C., Caskey, J., Pan, Z., and Murphy, J. A phase I study of daily carboplatin and simultaneous accelerated hyperfractionated chest irradiation (CRT) in patients with regionally inoperable non-small cell lung cancer (NSCLC). Int. J. Radial. Oncol. Biol. Phys., 40: 559-567, 1998.
122. Takada, Y., Furuse, K., Fukuoka, M., Nishikawa, Y. H., Katagami, N., and Ariyoshi, Y. A randomized Phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): preliminary analysis. Lung Cancer, 18 (Suppl. 1): 76-77, 1997.
123. Leonard, C. E., Chan, D. C., Chou, T. C., Kumar R., and Bunn, P. A., Jr. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res., 56: 5198-5204, 1996.
124. McGinn, C. J., Sherwach, D. S., and Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.
125. Okishio, K., Kudoh, S., Kurihara, N., Hirata, K., Tamura, K., Takeda, M., and Takeda, T. Irinotecan (CPT-11) enhances the radiosensitivity of lung cancer cells in vitro. Cell. Pharmacol., 3: 247-252, 1996.
126. Choy, H., Akerly, W., Safran, H., Clark, J., Rege, V., Papa, A., Glantz, M., Puthawala, Y., Soderberg, C., and Leone, L. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J. Clin. Oncol., 12: 2682-2686, 1994.
127. Greco, F. A., Stroup, S. L., Gray, J. R., and Hainsworth, J. D. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small cell lung cancer. J. Clin. Oncol., 14: 1642-1648, 1996.
128. Langer, C. J., Movas, B., Hudes, R., Schol, J., Keenan, E., Kilpatrick, D., Young, C., and Curran, W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin. Oncol., 24 (Suppl. 12): 89-95, 1997.
129. Lawrence, T. S., Eisbruch, A., and Shewarch, D. S. Gemcitabine-mediated radiosensitization. Semin. Oncol., 24 (Suppl. 7): 24-28, 1997.
130. Gregor, A. Gemcitabine plus radiotherapy for non-small cell lung cancer. Semin. Oncol., 24: 39-41, 1997.
131. Marini, N., Kris, M. G., Gralla, R. J., Bains, M. S., McCormack, P. M., Kaiser, L. R., Burt, M. E., and Zaman, M. B. The effects of pre-operative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal node metastases. Ann. Thorac. Surg., 45: 370, 1988.
132. Shepherd, F. A. Induction chemotherapy for locally advanced non-small cell lung cancer. Ann. Thorac. Surg., 55: 1585-1592, 1993.
133. Wagner, H., Jr., Lad, T., Piontadosi, S., and Ruckdeschel, J. C. Randomized Phase II evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine and cisplatin in patients with technically unresectable stage III A and III B non-small cell cancer of the lung: LCSG 881. Chest, 706 (Suppl. 6): 348s-354s, 1994.
134. Strauss, G. M., Herndon, J. E., Sherman, D. D., Mathisen, D. J., Carey, R. W., Choi, N. C., Rege, V. B., Modeas, C., and Green, M. R. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage III A non-small cell carcinoma of the lung: report of a Cancer and Leukemia Group B Phase II study. J. Clin. Oncol., 10: 1237-1244, 1992.
135. Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig. J., Olazabal, A., Canela, M., Ariza, A., Skacel, Z., Morera-Prat, J., and Abad, A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N. Engl. J. Med., 330: 153-158, 1994.
136. Roth, J. A., Fossella, F., Kamoki, R., Rayan, M. B., Putnam, J. B., Jr., Lee, J. S., Dhingra, H., DeCaro, L., Chasen, M., McGavran, M., Atkinson, N., and Hong, W. K. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J. Natl. Cancer Inst., 86: 673-680, 1994.
137. Crook, A., Duffy, A., Girling, D. J., Souhami, R. L., and Parmar, M. K. B. Survey on the treatment of non-small cell lung cancer in England and Wales. Lung Cancer, 18 (Suppl. 1): 9, 1997.
138. Yellan, S. B., and Cella, D. F. Someone to live for: social well being, parenthood states, and decision making in oncology. J. Clin. Oncol., 13: 1255-1264, 1995.
139. Pisters, K., Kris, M., Bunn, P. A., Jr., Johnson, D. J., Ruckdeschel, J. C., Crowley, J. J., Ginsberg, R. J., and the Bimodality Lung Oncology Team (BLOT). Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Semin. Oncol., 24 (Suppl. 12): 41-44, 1997.